Icon Advisers’s Amneal Pharmaceuticals AMRX Stock Holding History

Icon Advisers’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-128,042	Closed	-$918K	–	291
2019 Q2	$918K	Hold	128,042	–	–	0.09%	208
2019 Q1	$1.81M	Sell	128,042 -37,700	-23%	-$498K	0.18%	130
2018 Q4	$2.24M	Buy	165,742 +133,242	+410%	+$2.4M	0.24%	110
2018 Q3	$721K	Buy	32,500 +3,300	+11%	+$69.4K	0.06%	234
2018 Q2	$479K	Buy	+29,200	New	+$512K	0.04%	264

Other funds holding AMRX

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Icon Advisers's AMRX Position: Q3 2019 in Review

Icon Advisers sold out of Amneal Pharmaceuticals (AMRX) in Q3 2019, closing a stake of 128,042 shares — an estimated $918K sold.

Icon Advisers first reported a position in AMRX in Q2 2018 and held it in 5 quarters. The position peaked at $2.24M in Q4 2018. 121 funds tracked by Wall St. Rank hold AMRX as of Q3 2019.

Icon Advisers reported no remaining Amneal Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Icon Advisers sold 128,042 Amneal Pharmaceuticals shares in Q3 2019, an estimated $918K.
Icon Advisers first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 5 quarters.
Icon Advisers's Amneal Pharmaceuticals position peaked at $2.24M in Q4 2018.
121 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2019.

Based on Icon Advisers's 13F filing for Q3 2019, filed 1 Nov 2019.